U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466381) titled 'Oxyhydrogen Nanobubble Infusion as a Complementary Therapy in Patients With Parkinsonism' on Sept. 03, 2025.
Brief Summary: The aim of this study was to determine the effect of oxyhydrogen nanobubble infusion on the degree of disease, cognitive function, and quality of life of patients with parkinsonism
Study Start Date: Nov. 01, 2024
Study Type: INTERVENTIONAL
Condition:
Parkinson Disease
Intervention:
DRUG: oxyhydrogen nanobubble infusion
H2 and O2 gas molecules encapsulated in nanobubbles
Recruitment Status: COMPLETED
Sponsor: dr. Siti Nurlaela, SpN
Information provided by (Responsible Party): dr. Siti Nurlaela, SpN, U...